Serotonin receptors are found in almost all animals and are even known to regulate longevity and behavioral aging in the primitive nematode, Caenorhabditis elegans.[5][6]
5-hydroxytryptamine receptors or 5-HT receptors, or serotonin receptors are found in the central and peripheral nervous systems.[1][2]
They can be divided into 7 families of G protein-coupled receptors which activate an intracellularsecond messenger cascade to produce an excitatory or inhibitory response. The exception to this is the 5-HT3 receptor which is a ligand-gated ion channel.
In 2014, a novel 5-HT receptor was isolated from the small white butterfly, Pieris rapae, and named pr5-HT8. It does not occur in mammals and shares relatively low similarity to the known 5-HT receptor classes.[7]
The 7general serotonin receptor classes include a total of 14 known serotonin receptors.[9] The 15th receptor 5-HT1P has been distinguished on the basis of functional and radioligand binding studies, its existence has never been definitely affirmed or refuted.[10][11] The specific types have been characterized as follows:[12][13][14]
More information Information on serotonin receptors (human isoforms if nothing else is stated), Receptor ...
Information on serotonin receptors (human isoforms if nothing else is stated)
Note that there is no 5-HT1C receptor since, after the receptor was cloned and further characterized, it was found to have more in common with the 5-HT2 family of receptors and was redesignated as the 5-HT2C receptor.[107]
The genes coding for serotonin receptors are expressed across the mammalian brain. Genes coding for different receptors types follow different developmental curves. Specifically, there is a developmental increase of HTR5A expression in several subregions of the human cortex, paralleled by a decreased expression of HTR1A from the embryonic period to the post-natal one.
[108]
A number of receptors were classed as "5-HT1-like" - by 1998 it was being argued that, since these receptors were "a heterogeneous population of 5-HT1B, 5-HT1D and 5-HT7" receptors the classification was redundant.[109]
Murakami H, Bessinger K, Hellmann J, Murakami S (July 2008). "Manipulation of serotonin signal suppresses early phase of behavioral aging in Caenorhabditis elegans". Neurobiology of Aging. 29 (7): 1093–1100. doi:10.1016/j.neurobiolaging.2007.01.013. PMID17336425. S2CID37671716.
Qi YX, Xia RY, Wu YS, Stanley D, Huang J, Ye GY (December 2014). "Larvae of the small white butterfly, Pieris rapae, express a novel serotonin receptor". Journal of Neurochemistry. 131 (6): 767–777. doi:10.1111/jnc.12940. PMID25187179. S2CID21621635.
Francken BJ, Jurzak M, Vanhauwe JF, Luyten WH, Leysen JE (November 1998). "The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells". European Journal of Pharmacology. 361 (2–3): 299–309. doi:10.1016/S0014-2999(98)00744-4. PMID9865521.
Malenka RC, Nestler EJ, Hyman SE (2009). Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nded.). New York: McGraw-Hill Medical. p.4. ISBN9780071481274. Similarly, little is known about which of serotonin's 14 known receptors must be activated to achieve an antidepressant response.
Brady ST (2012). Basic Neurochemistry - Principles of Molecular, Cellular and Medical Neurobiology (8thed.). Waltham, MA: USA: Elsevier. pp.320–321. ISBN978-0-12-374947-5.
Mitchell NA, Pepperell E, Ociepka S, Brown JD, Witherington J, Tuladhar B, etal. (July 2009). "5-hydroxyindalpine, an agonist at the putative 5-HT receptor, has no activity on human recombinant monoamine receptors but accelerates distension-induced peristalsis in mouse isolated colon". Neurogastroenterology and Motility. 21 (7): 760–e48. doi:10.1111/j.1365-2982.2009.01275.x. PMID19309442. S2CID9532359.
Glennon RA, Dukat M, Westkaemper RB (2000-01-01). "Serotonin Receptor Subtypes and Ligands". American College of Neurophyscopharmacology. Archived from the original on 21 April 2008. Retrieved 2008-04-11.
Carey RJ, DePalma G, Damianopoulos E, Shanahan A, Müller CP, Huston JP (February 2005). "Evidence that the 5-HT1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects". Brain Research. 1034 (1–2): 162–171. doi:10.1016/j.brainres.2004.12.012. PMID15713268. S2CID28356741.
de Boer SF, Koolhaas JM (December 2005). "5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis". European Journal of Pharmacology. 526 (1–3): 125–139. doi:10.1016/j.ejphar.2005.09.065. PMID16310183.
Ebenezer IS, Arkle MJ, Tite RM (May 2007). "8-Hydroxy-2-(di-n-propylamino)-tetralin inhibits food intake in fasted rats by an action at 5-HT1A receptors". Methods and Findings in Experimental and Clinical Pharmacology. 29 (4): 269–272. doi:10.1358/mf.2007.29.4.1075362. PMID17609739.
Wouters W, Tulp MT, Bevan P (May 1988). "Flesinoxan lowers blood pressure and heart rate in cats via 5-HT1A receptors". European Journal of Pharmacology. 149 (3): 213–223. doi:10.1016/0014-2999(88)90651-6. PMID2842163.
Horiuchi J, McDowall LM, Dampney RA (November 2008). "Role of 5-HT(1A) receptors in the lower brainstem on the cardiovascular response to dorsomedial hypothalamus activation". Autonomic Neuroscience. 142 (1–2): 71–76. doi:10.1016/j.autneu.2008.06.004. PMID18667366. S2CID20878941.
Nalivaiko E, Ootsuka Y, Blessing WW (August 2005). "Activation of 5-HT1A receptors in the medullary raphe reduces cardiovascular changes elicited by acute psychological and inflammatory stresses in rabbits". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 289 (2): R596–R604. doi:10.1152/ajpregu.00845.2004. PMID15802554. S2CID17426759.
Lucot JB (February 1994). "Antiemetic effects of flesinoxan in cats: comparisons with 8-hydroxy-2-(di-n-propylamino)tetralin". European Journal of Pharmacology. 253 (1–2): 53–60. doi:10.1016/0014-2999(94)90756-0. PMID8013549.
Ogren SO, Eriksson TM, Elvander-Tottie E, D'Addario C, Ekström JC, Svenningsson P, etal. (December 2008). "The role of 5-HT(1A) receptors in learning and memory". Behavioural Brain Research. 195 (1): 54–77. doi:10.1016/j.bbr.2008.02.023. PMID18394726. S2CID140205386.
Yasuno F, Suhara T, Nakayama T, Ichimiya T, Okubo Y, Takano A, etal. (February 2003). "Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory". The American Journal of Psychiatry. 160 (2): 334–340. doi:10.1176/appi.ajp.160.2.334. PMID12562581.
Kennett GA, Dourish CT, Curzon G (February 1987). "Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression". European Journal of Pharmacology. 134 (3): 265–274. doi:10.1016/0014-2999(87)90357-8. PMID2883013.
Bardin L, Tarayre JP, Malfetes N, Koek W, Colpaert FC (April 2003). "Profound, non-opioid analgesia produced by the high-efficacy 5-HT(1A) agonist F 13640 in the formalin model of tonic nociceptive pain". Pharmacology. 67 (4): 182–194. doi:10.1159/000068404. PMID12595749. S2CID25882138.
Millan MJ, Perrin-Monneyron S (March 1997). "Potentiation of fluoxetine-induced penile erections by combined blockade of 5-HT1A and 5-HT1B receptors". European Journal of Pharmacology. 321 (3): R11–R13. doi:10.1016/S0014-2999(97)00050-2. PMID9085055.
Prow MR, Martin KF, Heal DJ (December 1996). "8-OH-DPAT-induced mydriasis in mice: a pharmacological characterisation". European Journal of Pharmacology. 317 (1): 21–28. doi:10.1016/S0014-2999(96)00693-0. PMID8982715.
Meyer LC, Fuller A, Mitchell D (February 2006). "Zacopride and 8-OH-DPAT reverse opioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 290 (2): R405–R413. doi:10.1152/ajpregu.00440.2005. PMID16166206. S2CID224414.
Popova NK, Amstislavskaya TG (July 2002). "Involvement of the 5-HT(1A) and 5-HT(1B) serotonergic receptor subtypes in sexual arousal in male mice". Psychoneuroendocrinology. 27 (5): 609–618. doi:10.1016/S0306-4530(01)00097-X. PMID11965359. S2CID25269315.
Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (May 2007). "A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy")". Neuroscience. 146 (2): 509–514. doi:10.1016/j.neuroscience.2007.02.032. PMID17383105. S2CID15617471.
Gudelsky GA, Koenig JI, Meltzer HY (December 1986). "Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors". Neuropharmacology. 25 (12): 1307–1313. doi:10.1016/0028-3908(86)90101-2. PMID2951611. S2CID2547042.
"BRINTELLIX (vortioxetine) tablets for oral use. Full Prescribing Information, Section 12.2 (Pharmacodynamics)." Takeda Pharmaceuticals America Inc. and Lundbeck, 2013. Revised September 2013. Archived 2019-09-18 at the Wayback Machine
Saxena PR, Lawang A (October 1985). "A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors". Archives Internationales de Pharmacodynamie et de Therapie. 277 (2): 235–252. PMID2933009.
Chojnacka-Wójcik E, Kłodzińska A, Tatarczyńska E (February 2005). "The anxiolytic-like effect of 5-HT1B receptor ligands in rats: a possible mechanism of action". The Journal of Pharmacy and Pharmacology. 57 (2): 253–257. doi:10.1211/0022357055399. PMID15720791. S2CID20743875.
Lin D, Parsons LH (April 2002). "Anxiogenic-like effect of serotonin(1B) receptor stimulation in the rat elevated plus-maze". Pharmacology, Biochemistry, and Behavior. 71 (4): 581–587. doi:10.1016/S0091-3057(01)00712-2. PMID11888549. S2CID21610537.
Tatarczyńska E, Kłodzińska A, Stachowicz K, Chojnacka-Wójcik E (December 2004). "Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression". Behavioural Pharmacology. 15 (8): 523–534. doi:10.1097/00008877-200412000-00001. PMID15577451. S2CID6940756.
Eriksson TM, Madjid N, Elvander-Tottie E, Stiedl O, Svenningsson P, Ogren SO (June 2008). "Blockade of 5-HT 1B receptors facilitates contextual aversive learning in mice by disinhibition of cholinergic and glutamatergic neurotransmission". Neuropharmacology. 54 (7): 1041–1050. doi:10.1016/j.neuropharm.2008.02.007. hdl:10616/40922. PMID18394658. S2CID207223573.
McCreary AC, Bankson MG, Cunningham KA (September 1999). "Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors". The Journal of Pharmacology and Experimental Therapeutics. 290 (3): 965–973. PMID10454466.
Feuerstein TJ, Hüring H, van Velthoven V, Lücking CH, Landwehrmeyer GB (May 1996). "5-HT1D-like receptors inhibit the release of endogenously formed [3H]GABA in human, but not in rabbit, neocortex". Neuroscience Letters. 209 (3): 210–214. doi:10.1016/0304-3940(96)12637-9. PMID8736648. S2CID27376524.
Bubar MJ, Cunningham KA (2006). "Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence". Current Topics in Medicinal Chemistry. 6 (18): 1971–1985. doi:10.2174/156802606778522131. PMID17017968.
Schreiber R, Melon C, De Vry J (February 1998). "The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test". Psychopharmacology. 135 (4): 383–391. doi:10.1007/s002130050526. PMID9539263. S2CID22677071.
Popova NK, Amstislavskaya TG (July 2002). "5-HT2A and 5-HT2C serotonin receptors differentially modulate mouse sexual arousal and the hypothalamo-pituitary-testicular response to the presence of a female". Neuroendocrinology. 76 (1): 28–34. doi:10.1159/000063681. PMID12097814. S2CID42319246.
Duxon MS, Kennett GA, Lightowler S, Blackburn TP, Fone KC (1997). "Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat". Neuropharmacology. 36 (4–5): 601–608. doi:10.1016/S0028-3908(97)00042-7. PMID9225285. S2CID41471226.
Kennett GA, Trail B, Bright F (December 1998). "Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated". Neuropharmacology. 37 (12): 1603–1610. doi:10.1016/S0028-3908(98)00115-4. PMID9886683. S2CID7310462.
Millan MJ, Brocco M, Gobert A, Dekeyne A (February 2005). "Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade". Psychopharmacology. 177 (4): 448–458. doi:10.1007/s00213-004-1962-z. PMID15289999. S2CID20866665.
Fujitsuka N, Asakawa A, Hayashi M, Sameshima M, Amitani H, Kojima S, etal. (May 2009). "Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin". Biological Psychiatry. 65 (9): 748–759. doi:10.1016/j.biopsych.2008.10.031. PMID19058784. S2CID22053616.
Millan MJ, Peglion JL, Lavielle G, Perrin-Monneyron S (April 1997). "5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists". European Journal of Pharmacology. 325 (1): 9–12. doi:10.1016/S0014-2999(97)89962-1. PMID9151932.
Stancampiano R, Melis MR, Argiolas A (August 1994). "Penile erection and yawning induced by 5-HT1C receptor agonists in male rats: relationship with dopaminergic and oxytocinergic transmission". European Journal of Pharmacology. 261 (1–2): 149–155. doi:10.1016/0014-2999(94)90313-1. PMID8001637.
Pitsikas N, Brambilla A, Borsini F (January 1994). "Effect of DAU 6215, a novel 5-HT3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task". Pharmacology, Biochemistry, and Behavior. 47 (1): 95–99. doi:10.1016/0091-3057(94)90116-3. PMID8115433. S2CID21800364.
Compan V, Charnay Y, Dusticier N, Daszuta A, Hen R, Bockaert J (2004). "[Feeding disorders in 5-HT4 receptor knockout mice]". Journal de la Société de Biologie. 198 (1): 37–49. doi:10.1051/jbio/2004198010037. PMID15146954. S2CID90408378.
Fontana DJ, Daniels SE, Wong EH, Clark RD, Eglen RM (1997). "The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation". Neuropharmacology. 36 (4–5): 689–696. doi:10.1016/S0028-3908(97)00055-5. PMID9225295. S2CID46510811.
Galeotti N, Ghelardini C, Bartolini A (September 1998). "Role of 5-HT4 receptors in the mouse passive avoidance test". The Journal of Pharmacology and Experimental Therapeutics. 286 (3): 1115–1121. PMID9732367.
Nelson DL (February 2004). "5-HT5 receptors". Current Drug Targets. CNS and Neurological Disorders. 3 (1): 53–58. doi:10.2174/1568007043482606. PMID14965244.
Wesołowska A (February 2008). "The anxiolytic-like effect of the selective 5-HT6 receptor antagonist SB-399885: the impact of benzodiazepine receptors". European Journal of Pharmacology. 580 (3): 355–360. doi:10.1016/j.ejphar.2007.11.022. PMID18096153.
Wesołowska A, Nikiforuk A (April 2007). "Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression". Neuropharmacology. 52 (5): 1274–1283. doi:10.1016/j.neuropharm.2007.01.007. PMID17320917. S2CID22664564.
Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, etal. (December 2006). "SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models". European Journal of Pharmacology. 553 (1–3): 109–119. doi:10.1016/j.ejphar.2006.09.049. PMID17069795.
Perez-García G, Meneses A (July 2005). "Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task". Pharmacology, Biochemistry, and Behavior. 81 (3): 673–682. doi:10.1016/j.pbb.2005.05.005. PMID15964617. S2CID19789219.
Wesołowska A, Nikiforuk A (March 2008). "The selective 5-HT(6) receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats". European Journal of Pharmacology. 582 (1–3): 88–93. doi:10.1016/j.ejphar.2007.12.013. PMID18234190.
Wesołowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E (September 2006). "Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression". Neuropharmacology. 51 (3): 578–586. doi:10.1016/j.neuropharm.2006.04.017. PMID16828124. S2CID39928418.
Gasbarri A, Cifariello A, Pompili A, Meneses A (December 2008). "Effect of 5-HT(7) antagonist SB-269970 in the modulation of working and reference memory in the rat". Behavioural Brain Research. 195 (1): 164–170. doi:10.1016/j.bbr.2007.12.020. PMID18308404. S2CID12910296.
Liy-Salmeron G, Meneses A (2008). "Effects of 5-HT drugs in prefrontal cortex during memory formation and the ketamine amnesia-model". Hippocampus. 18 (9): 965–974. doi:10.1002/hipo.20459. PMID18570192. S2CID20937527.
Bonaventure P, Kelly L, Aluisio L, Shelton J, Lord B, Galici R, etal. (May 2007). "Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents". The Journal of Pharmacology and Experimental Therapeutics. 321 (2): 690–698. doi:10.1124/jpet.107.119404. PMID17314195. S2CID14579645.
Saxena PR, De Vries P, Villalón CM (August 1998). "5-HT1-like receptors: a time to bid goodbye". Trends in Pharmacological Sciences. 19 (8): 311–316. doi:10.1016/S0165-6147(98)01228-0. PMID9745358.